Clinical Trials | October 16, 2025
Merck’s DOR/ISL regimen shows minimal impact on weight and lipids in phase 3 HIV studies
These findings follow positive Phase 3 results presented earlier this year
These findings follow positive Phase 3 results presented earlier this year
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
Investment to expand manufacturing and global medicine supply capacity
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
Subscribe To Our Newsletter & Stay Updated
